New Aspects of the Treatment of Patients with Low-Risk Myelodysplastic Syndromes

Publisher： Karger

E-ISSN： 2296-5262|23|1|12-16

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.1, 2000-03, pp. : 12-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 104-107

Karger

Access to resources Recommend Favorite

Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

By Villegas A.   Arrizabalaga B.   Fernáández-Lago C.   Castro M.   Mayans J.R.   Gonzáález-Porras J.R.   Duarte R.F.   Remacha A.F.   Luñño E.   Gasquet J.A.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 951-960

Informa Healthcare

Access to resources Recommend Favorite

Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload

By  

Acta Haematologica, Vol. 138, Iss. 2, 2017-09 ,pp. : 119-128

Karger

Access to resources Recommend Favorite

Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better?

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 1036-1040

John Wiley & Sons Inc

Access to resources Recommend Favorite

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1670-1676

John Wiley & Sons Inc

Access to resources Recommend Favorite